Telix Pharmaceuticals (TLX) Current Leases (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Current Leases of $5.5 million for Q4 2025, up 239.89% year-over-year from $1.6 million in Q4 2024, and up 239.89% quarter-over-quarter from $1.6 million in Q4 2024.
Telix Pharmaceuticals (TLX) Current Leases (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Current Leases for 3 consecutive years, with $5.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Leases rose 239.89% year-over-year to $5.5 million; the TTM figure through Dec 2025 stood at $5.5 million (up 239.89% YoY), while the FY2025 annual figure was $5.5 million, up 258.86% from the prior year.
- Current Leases rose to $5.5 million in Q4 2025 per TLX's latest filing, from $1.6 million in the prior quarter.
- Across five years, Current Leases topped out at $5.5 million in Q4 2025 and bottomed at $387339.3 in Q4 2023.
- Historically, Current Leases has averaged $2.5 million across 3 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2024 — Current Leases jumped 321.41% — and 2025, when it jumped 239.89%.
- Telix Pharmaceuticals' Current Leases stood at $387339.3 in 2023, then surged by 321.41% to $1.6 million in 2024, then surged by 239.89% to $5.5 million in 2025.
- Business Quant data shows TLX's Current Leases at $5.5 million in Q4 2025, $1.6 million in Q4 2024, and $387339.3 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | 5.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.55 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Dec 31, 2023 | 387,339.34 |